Niels Wenstedt | Getty Images
Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer.
J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present the full results at a medical meeting later this year.
“This is an absolute igniter,” said Biljana Naumovic, president of U.S. Oncology Solid Tumor at Johnson & Johnson Innovative Medicine. “People were looking for an overall survival difference.”
J&J is trying to supplant AstraZeneca’s blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR…
